default author photo

Satoru Miura

Niigata Cancer Center Hospital

Kawagishimachi, Chuo-Ku

Niigata 951-8566

Japan

SCHOLARLY PAPERS

3

DOWNLOADS

236

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Atezolizumab with Carboplatin Plus Nab-Paclitaxel Combination Therapy for TTF-1 Negative Advanced Nonsquamous Non–Small Cell Lung Cancer: A Multicenter, Single-Arm Phase 2 Trial (F1NE TUNE, LOGiK 2102)

Number of pages: 22 Posted: 16 Jul 2025
Kyushu University, affiliation not provided to SSRN, Kobe University, Kitakyushu Municipal Medical Center, affiliation not provided to SSRN, affiliation not provided to SSRN, Sendai Kousei Hospital, Kyoto Prefectural University of Medicine, affiliation not provided to SSRN, Kumamoto Regional Medical Center - Department of Respiratory Medicine, Iizuka Hospital, Kurume University - Kurume University Hospital, Saiseikai Kumamoto Hospital, Kumamoto Chuo Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, Shonan Kamakura General Hospital, affiliation not provided to SSRN, Tohoku University - Tohoku University Hospital, Fukuoka University Chikushi Hospital, affiliation not provided to SSRN, Saga University, affiliation not provided to SSRN, Niigata Cancer Center Hospital, affiliation not provided to SSRN and Kyushu University - Kyushu University Hospital
Downloads 145 (521,245)

Abstract:

Loading...

Immune checkpoint inhibitor, Atezolizumab, Carboplatin, nab-paclitaxel, Nonsquamous non-small cell lung cancer

2.

Daily low-dose carboplatin or weekly carboplatin plus nab-paclitaxel for concurrent chemoradiotherapy in older patients with locally advanced non-small cell lung cancer (JCOG1914): A randomized phase 3 trial

Number of pages: 42 Posted: 05 Dec 2025
affiliation not provided to SSRN, Shizuoka Cancer Center - Division of Thoracic Oncology, University of Tokyo - Department of Biostatistics and Bioinformatics, Shizuoka Cancer Center, affiliation not provided to SSRN, Shizuoka Cancer Center, Nagoya University, National Cancer Center Hospital East, National Cancer Center Hospital, National Hospital Organization Nagoya Medical Center, Hiroshima University - Hiroshima University Hospital, Kurashiki Central Hospital - Department of Respiratory Medicine, affiliation not provided to SSRN, affiliation not provided to SSRN, Kanagawa Cancer Center, affiliation not provided to SSRN, Kansai Medical University, Kurume University - Department of Internal Medicine, Kyushu University, National Center for Global Health and Medicine, Niigata Cancer Center Hospital, Osaka City General Hospital, Kyoto University, affiliation not provided to SSRN, National Cancer Center Hospital, National Cancer Center Hospital, Kyushu University - Kyushu University Hospital and Shizuoka Cancer Center
Downloads 61 (1,031,043)

Abstract:

Loading...

locally advanced, Non-small cell lung cancer (NSCLC), older patients, chemoradiotherapy, daily low-dose carboplatin, carboplatin plus nab-paclitaxel

3.

Multicenter real-world data on first-line chemoimmunotherapy in patients with advanced non-small cell lung cancer and performance status 2: WJOG18424L

Number of pages: 45 Posted: 01 Oct 2025
affiliation not provided to SSRN, Juntendo University, Shizuoka Cancer Center, Juntendo University, Wakayama Medical University, Kindai University, Sendai Kousei Hospital, Kurashiki Central Hospital - Department of Respiratory Medicine, Kanagawa Cancer Center, affiliation not provided to SSRN, Kindai University, Niigata Cancer Center Hospital, Osaka International Cancer Institute, Kobe University, Kyushu University - Kyushu University Hospital, Kobe City Medical Center General Hospital, Kanagawa Cardiovascular and Respiratory Center, Kumamoto University - Kumamoto University Hospital, Hiroshima University - Hiroshima University Hospital, Nagasaki University, Wakayama Medical University - Department of Pulmonary Medicine and Medical Oncology, Kyushu University - Kyushu University Hospital and Juntendo University - Department of Respiratory Medicine
Downloads 30 (1,332,057)

Abstract:

Loading...

Non-small cell lung cancer, Performance status 2, Immune checkpoint inhibitors, Real-world evidence, First-line therapy